Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Please provide your email address to receive an email when new articles are posted on . The Clareon family of IOLs is now available in the U.S., with an international rollout set to take place ...
“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix,” said Rob ...
Clareon PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%31-34; PanOptix® Trifocal IOL, implanted over 2.2 ...
Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom ...
TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across ...
GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results